A trial of RIT-4237 rotavirus vaccine in
β
I. D. Mutz; F. Krainer; J. Deutsch; Ch. Kunz; D. E. Teuwen
π
Article
π
1989
π
Springer
π
English
β 236 KB
In a double blind placebo-controlled study rotavirus vaccine RIT 4237 was offered to young infants after the fourth week of life. The vaccine was very well tolerated. Fifty-seven out of 100 vaccine recipients and 10 out of 103 placebo recipients developed rotavirus-IgM-antibodies during the 1 month